Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Median Duration Of Response And 91% One-Year Overall Survival Rate In Advanced Melanoma Patients With High PRAME Expression

Loading news article.

Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Median Duration Of Response And 91% One-Year Overall Survival Rate In Advanced Melanoma Patients With High PRAME Expression | WAPE

Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Median Duration Of Response And 91% One-Year Overall Survival Rate In Advanced Melanoma Patients With High PRAME Expression

Article summary

Related companies

Comments —